Pharmacologic regulation of histamine release by the human recombinant histamine-releasing factor
Summary
This summary is machine-generated.Human histamine releasing factor (HrHRF) may use a unique signaling pathway, distinct from the IgE receptor. Rottlerin selectively modulated HrHRF-induced histamine release, supporting a novel receptor interaction.
Area Of Science
- Immunology
- Cell Signaling
Background
- Human recombinant IgE-dependent histamine releasing factor (HrHRF) was initially believed to interact with IgE on basophils to trigger histamine release.
- Emerging evidence suggests HrHRF may bind to a distinct cell surface receptor, independent of IgE.
Purpose Of The Study
- To investigate if the HrHRF signaling pathway differs from the high-affinity IgE receptor (FcεRI) pathway.
- To differentiate HrHRF's mechanism from IgE-dependent and IgE-independent histamine release pathways.
Main Methods
- Compared the effects of pharmacologic agents (staurosporine, Bis II, Gö 6976, rottlerin, pertussis toxin) on histamine release from human basophils.
- Tested stimuli including HrHRF, anti-IgE antibody, antigen, and FMLP (formylated tripeptide).
Main Results
- Rottlerin uniquely enhanced HrHRF-mediated histamine release.
- Rottlerin inhibited FMLP-induced histamine release but did not affect anti-IgE or antigen-induced release.
- Other tested modulators did not differentiate HrHRF from IgE-dependent pathways.
Conclusions
- The data indicate a unique signaling pathway for HrHRF.
- This supports the hypothesis that HrHRF binds to a specific receptor distinct from IgE.
View abstract on PubMed